ストックスクリーナーアプリを入手
11.30
33.89%
2.86
前日終値:
$8.44
開ける：
$9.6
24時間の取引高:
26,212
Relative Volume:
0.49
時価総額：
$74.11M
収益：
$28.83M
当期純損益:
$-13.34M
株価収益率:
-7.4342
EPS:
-1.52
ネットキャッシュフロー:
$-7.49M
1週間 パフォーマンス:
-3.67%
1か月 パフォーマンス:
-19.57%
6か月 パフォーマンス:
+331.30%
1年 パフォーマンス:
+302.85%
1日の値動き範囲:
$9.60
$11.44
1週間の範囲:
$8.28
$12.29
52週間の値動き範囲:
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
XCUR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.2499 | 398.00M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
19.82 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1627 | 347.36M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
JUNE
Dhandho Junoon Etf
|
10.98 | 204.17M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.93 | 131.34M | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 開始されました | BMO Capital Markets | Outperform |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
Exicure Inc (XCUR) 最新ニュース
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma | XCUR Stock News - GuruFocus
Exicure appoints new independent accounting firm By Investing.com - Investing.com South Africa
Exicure appoints new independent accounting firm - Investing.com
Breakthrough: New Multiple Myeloma Treatment Achieves Perfect Success Rate in Trial - Stock Titan
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
New Clinical Trial: Exicure's GPC-100 Shows Promise in Fighting Acute Myeloid Leukemia - Stock Titan
How to Take Advantage of moves in (XCUR) - news.stocktradersdaily.com
Eli Lilly and Company (NYSE:LLY) and Exicure (NASDAQ:XCUR) Head to Head Analysis - Defense World
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Grows By 58.5% - Defense World
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks - Investing.com India
Wednesday’s Insider Moves: Top Buys and Sells in US Stocks By Investing.com - Investing.com UK
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
Major Investment Alert: HiTron Systems Inc. Boosts Stake in Exicure! - TipRanks
HiTron Systems acquires $8.7 million in Exicure stock By Investing.com - Investing.com Canada
HiTron Systems acquires $8.7 million in Exicure stock - Investing.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exicure, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm - Business Wire
Exicure Inc Reports $9.7 Million Net Loss for Fiscal Year 2024 A - GuruFocus
Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference - Business Wire
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2% - Defense World
Exicure, Inc. Reports Full Year 2024 Financial Results - BioSpace
EXICURE, INC. SEC 10-K Report - TradingView
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Exicure, Inc. Investors to Secure Counsel Before Important February 11 Deadline in Securities Class Action – XCUR - Business Wire
Pre-Market Momentum: Exicure (XCUR) Shares Rise After Key Approval - Stocks Telegraph
When (XCUR) Moves Investors should Listen - Stock Traders Daily
Exicure Gets Patent in Australia for Potential Cancer Treatment Combination -March 14, 2025 at 04:32 am EDT - Marketscreener.com
Exicure secures Australian patent for cancer treatment - Investing.com Australia
Exicure, Inc. Announces Issuance Of New Patent In Australia -March 13, 2025 at 05:39 pm EDT - Marketscreener.com
Exicure announces issuance of new patent in Australia - TipRanks
Exicure secures Australian patent for cancer treatment By Investing.com - Investing.com South Africa
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia - Business Wire
Exicure's New Cancer Patent Breakthrough Powers Multiple Myeloma Clinical Trial - Stock Titan
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Exicure announces board member departures, transitions By Investing.com - Investing.com Australia
(XCUR) Technical Pivots with Risk Controls - Stock Traders Daily
Exicure announces board member departures, transitions - Investing.com
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 16.2% in February - Defense World
Where are the Opportunities in (XCUR) - Stock Traders Daily
Exicure (NASDAQ:XCUR) Stock Price Down 1.6% – Time to Sell? - Defense World
Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes - MSN
How To Trade (XCUR) - Stock Traders Daily
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
How the (XCUR) price action is used to our Advantage - Stock Traders Daily
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 17.3% in January - Defense World
Hitron Systems Inc. announced that it expects to receive KRW 30 billion in funding -September 05, 2024 - Marketscreener.com
Exicure Inc (XCUR) requires closer examination - US Post News
Exicure signs purchase agreement with GPCR Therapeutics - MSN
Exicure, back from brink and under new management, buys GPCR's US unit and clinical-stage drug - Fierce Biotech
Exicure Inc (XCUR) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):